ES2139591T3 - Asialoglicoproteinas del virus de la hepatitis c. - Google Patents

Asialoglicoproteinas del virus de la hepatitis c.

Info

Publication number
ES2139591T3
ES2139591T3 ES92900091T ES92900091T ES2139591T3 ES 2139591 T3 ES2139591 T3 ES 2139591T3 ES 92900091 T ES92900091 T ES 92900091T ES 92900091 T ES92900091 T ES 92900091T ES 2139591 T3 ES2139591 T3 ES 2139591T3
Authority
ES
Spain
Prior art keywords
hcv
asialoglycoprotein
region
expressed
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92900091T
Other languages
English (en)
Other versions
ES2139591T5 (es
Inventor
Robert O Ralston
Frank Marcus
Kent B Thudium
Barbara A Gervase
John A Hall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27417050&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2139591(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ES2139591T3 publication Critical patent/ES2139591T3/es
Publication of ES2139591T5 publication Critical patent/ES2139591T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Una asialoglicoproteína del virus de la hepatitis C (HCV) seleccionada entre una asialigricoproteína expresada en la región E1 del HCV y una asialoglicoproteína expresada en la región E2 del HCV, y agregados de las mismas, pudiéndose obtener dicha asialoglicoproteína mediante el método que comprende las etapas de: (i) cultivar una célula hospedante de mamífero tranformada con un gen estructural que codifica una asialoglicoproteína de HCV expresada en la región E1 de HCV, de la región E2 de HCV o de ambas, en un medio de cultivo adecuado, estando dicho gen estructural unido a una secuencia que codifica un conductor de la secreción que dirige a la asialoglicoproteína hacia el retículo endoplásmico; (ii) provocar la expresión de dicho gen estructural y conductor de la secreción, bajo condiciones que inhiben la sialilación; en el que dichas condiciones que inhiben la sialilación comprenden inhibir el transporte de las glicoproteínas desde el retículo endoplásmico hacia el aparato de Golgi de las células; y (iii) aislar dicha asialoglicoproteína de HCV del cultivo celular peoniendo en contacto dicha asialoglicoproteína de HCV con una proteína de unión a manosa, específica para glicoproteínas terminadas en manosa, en la que menos de aproximadamente 10% de los carbohidratos N-unidos totales son ácido siálico.
ES92900091T 1990-11-08 1991-11-07 Asialoglicoproteinas del virus de la hepatitis c. Expired - Lifetime ES2139591T5 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US61196590A 1990-11-08 1990-11-08
US61141990A 1990-11-08 1990-11-08
US611419 1990-11-08
US75888091A 1991-09-13 1991-09-13
US758880 1991-09-13

Publications (2)

Publication Number Publication Date
ES2139591T3 true ES2139591T3 (es) 2000-02-16
ES2139591T5 ES2139591T5 (es) 2007-08-01

Family

ID=27417050

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92900091T Expired - Lifetime ES2139591T5 (es) 1990-11-08 1991-11-07 Asialoglicoproteinas del virus de la hepatitis c.

Country Status (17)

Country Link
EP (2) EP0842947B2 (es)
JP (8) JPH06504431A (es)
AT (1) ATE188220T1 (es)
AU (1) AU668078B2 (es)
CA (2) CA2203443C (es)
CZ (1) CZ289006B6 (es)
DE (1) DE69131882T3 (es)
DK (2) DK0842947T4 (es)
ES (1) ES2139591T5 (es)
FI (1) FI107803B (es)
GR (1) GR3032771T3 (es)
HU (2) HU227498B1 (es)
NO (2) NO304380B1 (es)
PT (2) PT99466B (es)
RO (1) RO115446B1 (es)
SK (3) SK286106B6 (es)
WO (1) WO1992008734A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274148B1 (en) 1990-11-08 2001-08-14 Chiron Corporation Hepatitis C virus asialoglycoproteins
JP3158177B2 (ja) * 1991-10-08 2001-04-23 国立感染症研究所長 C型肝炎診断薬
DE69333269T2 (de) * 1992-01-31 2004-07-29 Abbott Laboratories, Abbott Park Expressionssystem in säugetieren für hcv-proteine
UA39944C2 (uk) * 1992-07-07 2001-07-16 Чірон Корпорейшн Спосіб визначення ранньої сероконверсії у ссавця-хазяїна до вірусу гепатиту с і набір для використання в способі
JPH08510240A (ja) 1993-05-12 1996-10-29 カイロン コーポレイション C型肝炎ウイルスe2/ns1領域の保存モチーフ
US5514539A (en) * 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
US5610009A (en) * 1994-01-28 1997-03-11 Abbott Laboratories Mammalian expression systems for hepatitis C virus envelope genes
AU3241095A (en) * 1994-07-29 1996-03-04 Chiron Corporation Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same
EP1510580B1 (en) 1994-07-29 2008-12-10 Novartis Vaccines and Diagnostics, Inc. Hepatitis C E2 truncated polypeptide and methods of obtaining the same
DE69526636D1 (de) 1994-07-29 2002-06-13 Innogenetics Nv Gereinigte hepatitis-c-virus hüllproteine zur diagnostischen und therapeutischen verwendung
IT1271593B (it) * 1994-11-30 1997-06-04 Sanitaria Scaligera Spa Procedimento ed apparecchiatura per l'immunoadsorbimento specifico di virus hiv, di antigene gp120 e complesso cd4-gp120.
US6127116A (en) 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
FR2744725B1 (fr) * 1996-02-09 1998-04-30 Pasteur Institut Anticorps specifiques des complexes formes par les glycoproteines e1 et e2 du virus de l'hepatite c, procedes de determination de la presence, et d'isolement de ces complexes
US6514731B1 (en) 1996-05-24 2003-02-04 Chiron Corporation Methods for the preparation of hepatitis C virus multiple copy epitope fusion antigens
KR100209095B1 (ko) * 1996-06-28 1999-07-15 성재갑 C형 간염 바이러스의 프로테아제의 활성을 측정할 수 있는 c형 간염 대체 바이러스, 그 재조합 유전자 및 그 용도
DE69739268D1 (de) 1996-11-08 2009-04-02 Us Gov Health & Human Serv Herstellung und reinigung von hepatitis c virus-ähnlichen partikeln
US7338759B1 (en) 1997-03-04 2008-03-04 Washington University HCV variants
US7049428B1 (en) 1998-03-04 2006-05-23 Washington University HCV variants
ATE437951T1 (de) 1997-05-06 2009-08-15 Novartis Vaccines & Diagnostic Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2
EP0947525A1 (en) 1998-03-27 1999-10-06 Innogenetics N.V. Epitopes in viral envelope proteins and specific antibodies directed against these epitopes: use for detection of HCV viral antigen in host tissue
US7108855B2 (en) 1998-06-24 2006-09-19 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
DE60130998T2 (de) 2000-08-17 2008-07-17 Tripep Ab Ribavirin-enthaltende vakzine
RU2286172C2 (ru) 2000-08-17 2006-10-27 Трипеп Аб Вакцины, содержащие рибавирин, и способы их использования
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7101561B2 (en) 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
US20030232745A1 (en) * 2001-06-26 2003-12-18 Olson William C. Uses of DC-sign and DC-Signr for inhibiting hepatitis C virus infection
US7022323B2 (en) 2001-06-26 2006-04-04 Progenics Pharmaceuticals, Inc. Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
EP1551960A4 (en) * 2002-08-16 2006-02-01 Univ Ohio CLEANING HEPATITIS C VIRUS SIMILAR PARTICLE
CA2618429A1 (en) 2005-05-25 2007-03-22 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
US8071561B2 (en) 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
WO2009130588A2 (en) 2008-04-22 2009-10-29 Tripep Ab Immunogen platform

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1074422C (zh) * 1987-11-18 2001-11-07 希龙股份有限公司 制备含有hcv表位的分离多肽的方法
IL88599A0 (en) * 1987-12-10 1989-07-31 Cell Bio Group Ltd Glycoprotein cell growth modulating materials,their preparation and compositions containing them
JP2656995B2 (ja) * 1989-03-17 1997-09-24 カイロン コーポレイション Nanbvの診断用薬
JP2733138B2 (ja) * 1990-04-04 1998-03-30 カイロン コーポレイション 抗hcv抗体の免疫アッセイに使用するc型肝炎ウイルス(hcv)抗原の組合せ

Also Published As

Publication number Publication date
DE69131882D1 (en) 2000-02-03
AU668078B2 (en) 1996-04-26
CA2095521C (en) 2009-06-30
DK0556292T4 (da) 2006-12-27
DK0556292T3 (da) 2000-04-17
EP0556292B2 (en) 2006-11-29
JP2001286290A (ja) 2001-10-16
NO304381B1 (no) 1998-12-07
PT99466B (pt) 1999-04-30
DE69131882T3 (de) 2007-05-24
NO972213L (no) 1997-05-14
JP2008031181A (ja) 2008-02-14
PT99466A (pt) 1992-10-30
JP2003093081A (ja) 2003-04-02
EP0842947A2 (en) 1998-05-20
NO931680D0 (no) 1993-05-07
GR3032771T3 (en) 2000-06-30
FI932025L (fi) 1993-06-07
DK0842947T4 (da) 2009-06-08
SK285624B6 (sk) 2007-05-03
EP0842947A3 (en) 2001-12-12
HUT66063A (en) 1994-09-28
EP0556292A1 (en) 1993-08-25
AU9026791A (en) 1992-06-11
SK285623B6 (sk) 2007-05-03
CA2095521A1 (en) 1992-05-09
HU227498B1 (en) 2011-07-28
SK69097A3 (en) 1997-11-05
PT102022A (pt) 1999-01-29
JP4056306B2 (ja) 2008-03-05
NO931680L (no) 1993-06-28
CZ82493A3 (en) 1994-04-13
JP2005187479A (ja) 2005-07-14
NO972213D0 (no) 1997-05-14
JP2003174875A (ja) 2003-06-24
JP3207155B2 (ja) 2001-09-10
JPH1171395A (ja) 1999-03-16
CZ289006B6 (cs) 2001-10-17
EP0842947B1 (en) 2004-04-21
JPH06504431A (ja) 1994-05-26
EP0556292B1 (en) 1999-12-29
HU9301336D0 (en) 1993-10-28
SK286106B6 (sk) 2008-03-05
FI107803B (fi) 2001-10-15
NO304380B1 (no) 1998-12-07
RO115446B1 (ro) 2000-02-28
FI932025A0 (fi) 1993-05-05
JP2006219503A (ja) 2006-08-24
ES2139591T5 (es) 2007-08-01
SK44293A3 (en) 1993-08-11
EP0842947B2 (en) 2009-03-18
DE69131882T2 (de) 2000-05-04
WO1992008734A1 (en) 1992-05-29
CA2203443C (en) 2001-08-28
PT102022B (pt) 2000-12-29
EP0556292A4 (es) 1995-01-18
CA2203443A1 (en) 1992-05-09
DK0842947T3 (da) 2004-07-26
ATE188220T1 (de) 2000-01-15

Similar Documents

Publication Publication Date Title
ES2139591T3 (es) Asialoglicoproteinas del virus de la hepatitis c.
Ball et al. Glycosaminoglycans in bovine cumulus-oocyte complexes: morphology and chemistry
Dacheux et al. Protein secretion in the epididymis
Olsen et al. Interchain disulfide bonds at the COOH-terminal end of procollagen synthesized by matrix-free cells from chick embryonic tendon and cartilage
RU2009131610A (ru) Среда для культивирования клеток без белков и без сыворотки
Inoue et al. Are folliculo-stellate cells in the anterior pituitary gland supportive cells or organ-specific stem cells?
GR862185B (en) Production of pluripotent granulocyte colony-stimulating factor
CO5021164A1 (es) Genes de elongasa y sus usos
Katz et al. Membrane assembly: synthesis and intracellular processing of the vesicular stomatitis viral glycoprotein
KR900016261A (ko) 독사독 폴리펩티드 및 유전적 발현
DK162233C (da) Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii
ES8802394A1 (es) Un procedimiento para preparar una proteina de fusion derivada de la secuencia de aminoacidos de la preprorrelaxina humana.
Mundall et al. Physical and chemical characterization of vitellogenin from the hemolymph and eggs of the tobacco hornworm, Manduca sexta
DE60141014D1 (de) Verfharen zur herstellung von herpes-simplex-virus-amplikons, die resultierenden amplikons und ihre verwendung
EP1054063A3 (en) Process for the production of naturally folded and secreted proteins
KR910021477A (ko) 인체 단백질 c의 글리코실화 돌연변이체의 발현을 위한 벡터 및 화합물
YU172185A (en) Process for obtaining monoclonic anti-bodies
KR970002670B1 (ko) 고양이 인터페론 및 이의 제조방법
Handley et al. Characterization of the collagen synthesized by cultured cartilage cells
Do Ngoc et al. Sequence analysis of peptide fragments from the intrinsic membrane protein of calf lens fibers MP26 and its natural maturation product MP22
MX9600380A (es) Proceso de extraccion de proteinas periplasmicas de microorganismos procarioticos en presencia de arginina.
GB9225021D0 (en) Organic compounds
EP0163573A1 (en) Site-specific proteolysis by renin
Cantini et al. Differential expression of adult type MHC in satellite cell cultures from regenerating fast and slow rat muscles.
Quarto et al. Synthesis of seminal ribonuclease in isolated lobules of bull seminal vesicles

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 556292

Country of ref document: ES